Nuvessa is commonly used to help with Bacterial Vaginosis (BV), a condition arising from an imbalance of the vaginal microbiome associated with specific microbial imbalances.

The medication is applicable within clinical settings that involve acute or disruptive symptom patterns and is used to manage symptom clusters that may become intense or disruptive. The medication plays a role in easing the challenging symptoms often associated with BV, namely unusual vaginal discharge and a distinct, unpleasant odor. The localized, topical approach is relevant in situations requiring short-term symptomatic assistance.

The medication provides support that helps ease the overall burden of these symptoms, contributing to improved day-to-day comfort.

“This treatment supports general well-being during symptomatic phases and is relevant for managing symptoms that interfere with daily comfort.”

It is commonly used across conditions presenting with acute episodes and helps address the symptoms related to physical discomfort and those that interfere with daily functioning.

---

Quick Fact: Relief for Distressing Symptoms Nuvessa is relevant for easing the pronounced symptoms of BV, assisting with maintaining functional stability during episodes of heightened discomfort.

The eligibility for using Nuvessa (metronidazole vaginal gel 1.3%) is strictly defined by regulatory documents based on patient history and physiological status.

Contraindicated Populations

The medicine is contraindicated for patients with a known history of hypersensitivity to metronidazole, other nitroimidazole derivatives, parabens, or any other component of the formulation. It must not be used by patients who have taken the drug disulfiram (Antabuse) within the last two weeks.

Restricted Eligibility and Conditional Use

Category	Eligibility Rule
Age Restriction	Safety and effectiveness are not established in female children younger than 12 years of age.
Organ Function	Use must be cautious in patients with severe hepatic disease due to the risk of drug accumulation.
CNS Disorder	Administer with caution to patients with central nervous system diseases (e.g., history of seizures); discontinuation is required if abnormal neurological signs develop.
Co-Consumption	The consumption of alcohol (ethanol) or products containing propylene glycol is prohibited during treatment and for at least 24 hours after the last dose.
Pregnancy/Lactation	Pregnancy: No adequate and well-controlled studies exist; use only if clearly needed. Lactation: Breastfeeding is not recommended during treatment and for 48 hours after the last dose.

Interactions with other medicines and products

Nuvessa (metronidazole vaginal gel) has low systemic absorption, but its interaction profile includes important restrictions and warnings based on the known effects of oral metronidazole.

Contraindicated and Restricted Combinations

Interacting Substance	Regulatory Restriction	Practical Implication
Alcohol (Ethanol/Propylene Glycol)	Must be avoided during treatment and for at least 24 hours after therapy.	Risk of severe disulfiram-like reaction (flushing, nausea, vomiting, headache).
Disulfiram	Must not be administered concurrently or within two weeks of Nuvessa therapy.	Risk of severe psychotic reactions.

---

Clinically Significant Interactions

Co-administration with Nuvessa requires monitoring for the following:

• Oral Anticoagulants (e.g., Warfarin): Metronidazole can potentiate the anticoagulant effect, which may result in a clinically significant prolongation of Prothrombin Time/INR. Dosage adjustment of the anticoagulant may be necessary.
• Lithium: Use with metronidazole has been associated with elevated plasma lithium concentrations and potential toxicity, requiring careful monitoring.
• Cimetidine: This substance may decrease the plasma clearance and prolong the half-life of metronidazole, potentially increasing systemic exposure.

Selective Activation by Microbial Metabolism

The action of Metronidazole is initiated by its function as a prodrug, requiring chemical transformation to become active. This activation occurs exclusively in the low-oxygen, low-redox potential environment characteristic of susceptible anaerobic organisms. Specific electron-transport proteins, primarily ferredoxin, donate electrons to the drug's NO2 group, creating a highly unstable and destructive nitro-radical anion. This dependency on anaerobic chemistry establishes the functional range of the drug's activity.

---

Mechanism of Genetic Destruction and Clearance

Once the radical is formed, it attacks the organism's Deoxyribonucleic Acid (DNA), causing rapid, irreversible strand breaks and disrupting the helical structure. This direct molecular damage halts essential processes like replication and transcription, resulting in a concentration-dependent lethal action on the organism. The physiological consequence of this targeted genetic destruction is the reduction of the susceptible microbial population at the site of application.

---

Constraints on Action by Oxygen Competition

The mechanism's activity is constrained by the presence of oxygen, which acts as a competitive antagonist to the activation process. Oxygen re-oxidizes the active radical back to its inactive parent form, weakening the lethal mechanism. This constraint is the biological reason that the drug’s mechanism fails to activate against aerobic bacteria.

Official Administration Guidelines for Nuvessa

Administration of Nuvessa (metronidazole 1.3% vaginal gel) follows a specific, single-dose regimen. The administration details focus on the route, precise dosing, and required timing.

Category	Instruction
Route of administration	Intravaginal administration only. The product is not approved for ophthalmic, dermal, or oral use.
Dosing schedule	A single dose of one pre-filled disposable applicator, delivering approximately 65 mg of metronidazole in 5 grams of gel.
Frequency and Timing	Administered once as a complete, single-dose course, specifically to be used at bedtime.
Age-group considerations	Approved for use in females 12 years of age and older. Caution is noted for administration to patients with severe hepatic disease due to the potential for slower metronidazole metabolism.
Special Procedural Conditions	During the treatment period, patients are directed to avoid vaginal intercourse and not use other vaginal products such as douches or tampons. The product is supplied ready for use and requires no dilution.

---

Resulting Procedural Structure

The usage protocol establishes Nuvessa as a single-application, local treatment regimen. The medication is delivered via a pre-filled applicator and the entire course of therapy is completed with the sole application. This precise protocol dictates the route, dose, and frequency, confining the use to a one-time administration at bedtime, which defines the standardized approach for the product’s use.

Research Evidence / Overview of Studies for Nuvessa

---

Evidence from Clinical Trials for Bacterial Vaginosis (BV)

The core research examining Nuvessa (metronidazole vaginal gel 1.3%) was conducted using randomized controlled trials (RCTs). These are high-quality studies that compare the effects of the metronidazole gel against an inactive substance, known as a vehicle gel, to evaluate the outcomes measured in the active treatment group compared to the vehicle gel. The populations included in these pivotal trials were primarily adult women who had received a clinical diagnosis of Bacterial Vaginosis.

In these research settings, studies explored different outcomes related to physical discomfort and the clinical signs of the condition. Researchers monitored the rate of a clinical outcome measurement, which means assessing whether the signs of infection, such as specific types of vaginal discharge, odor presence, and certain cell changes, were observed to change by the end of the study. They also measured a composite therapeutic outcome, a broader outcome that combines the assessment of change in physical signs with a change in the vaginal microflora profile. Studies tracked the time to resolution for patient-reported outcomes describing perceived discomfort, particularly the clearance of odor and discharge.

Studies measured clinical outcomes at the primary follow-up time point, and the data observed in the active treatment group was compared against the vehicle control. This follow-up was typically scheduled between Day 21 and Day 30 after the treatment was administered.

---

Long-Term Research and Follow-up

The initial regulatory studies designed to evaluate Nuvessa focused primarily on research exploring short-term symptom changes and cure rates over a defined time interval, usually up to one month. The primary evidence thus contributes to understanding symptom patterns and microbial shifts only within the immediate weeks following application.

However, scientific literature notes that Bacterial Vaginosis is a condition characterized by fluctuating or episodic manifestations, and high rates of recurrence are reported across various antibiotic treatments for BV. Consequently, long-term effects are not fully established by the primary regulatory trials, and there is limited information for long-term outcomes regarding the durability of the measured outcomes. While studies provide insight into short-term changes, they do not comprehensively address the challenge of recurrence or long-term microbial balance.

---

Research Evidence in Specific Populations

Research was conducted to explore the effects of the gel in these groups. The core studies primarily focused on adult women, including non-pregnant participants ranging from 18 to 67 years old. Research was applied in studies examining patient-reported experiences and tolerability in adolescent females between the ages of 12 and 18 years. The research exploring the use in this adolescent population was conducted through an open-label study, with findings in adolescents often relying on extrapolation from the data observed in adult women. Conversely, there is data for certain groups remain insufficient; specifically, the clinical studies did not include enough subjects aged 65 years or older to determine if they respond differently than the younger adult study groups. Furthermore, due to the study design, populations with comorbid conditions or those who are pregnant were typically not included in the core clinical studies.

---

Understanding the Scientific Limitations and Research Gaps

The evidence supporting the short-term comparison against the vehicle control in the adult population is broadly classified as a high level of evidence, as it is derived from controlled, randomized trials. However, certain limitations exist.

One key limitation is that follow-up durations were limited in the pivotal trials, focusing on immediate outcomes rather than the long-term course of the condition. This means the evidence is limited regarding the durability of the measured clinical outcome over many months or years. The scientific challenge of high recurrence rates for BV highlights an area where existing research provides context but not individual predictions for patterns related to long-term symptom management. The results apply only to the populations studied, and findings describe group patterns, not personal outcomes, indicating that ongoing research is needed to better understand the long-term management of this condition.

Key Studies & References

1. Diagnosis and management of bacterial vaginosis: an overview
2. Recurrence of bacterial vaginosis: a review of the literature
3. Metronidazole Vaginal Gel - DailyMed (NIH)

Common questions about Nuvessa (FAQ)

Q: What is Nuvessa (metronidazole vaginal gel 1.3%) used for?

A: Nuvessa is a prescription medicine used to treat bacterial vaginosis (BV) in females 12 years of age and older. It contains the active ingredient metronidazole in a vaginal gel formulation.

---

Q: How do I use Nuvessa?

A: Nuvessa is administered using a single-dose, pre-filled disposable applicator once, intravaginally (into the vagina), typically at bedtime.

---

Q: What are the most common side effects of Nuvessa?

A: The most common side effects reported in adults were:

• Vaginal yeast infection (vulvovaginal candidiasis)
• Headache
• Vaginal itching (vulvovaginal pruritus)
• Nausea
• Diarrhea
• Menstrual cramps (dysmenorrhea)

In patients 12 to less than 18 years old, the most common side effect was vulvovaginal discomfort.

---

Q: What is the most important information I should know about Nuvessa?

A: You should not use Nuvessa if you:

• Are allergic to metronidazole, parabens, other ingredients in Nuvessa, or other nitroimidazole medicines.
• Are taking, or have taken within the last two weeks, a medicine called Antabuse (disulfiram).
• Are unwilling or unable to abstain from alcohol.

Do not drink alcohol or use products containing propylene glycol while using Nuvessa and for at least 24 hours after you stop using it, as severe flushing, nausea, and vomiting may occur.

Tell your healthcare provider if you experience convulsive seizures or numbness or pain in your arms and legs. These symptoms may be signs of serious side effects.

---

Q: Can I use tampons, douches, or have vaginal intercourse while using Nuvessa?

A: No. You should avoid having vaginal intercourse or using other vaginal products (such as tampons or douches) while using Nuvessa.

---

Q: What should I tell my doctor before using Nuvessa?

A: Tell your doctor about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Specific conditions and medicines to mention include:

• Central nervous system (CNS) diseases (past or present)
• If you are pregnant or plan to become pregnant
• If you are breastfeeding or plan to breastfeed
• Any medicine that contains warfarin or other coumarin blood thinners
• Lithium

---

Q: Can I use Nuvessa if I am pregnant or breastfeeding?

A: Pregnancy:

• It is not known if Nuvessa will harm an unborn baby. Tell your doctor if you are pregnant or become pregnant during treatment.

Breastfeeding:

• Nuvessa can pass into breast milk and may harm your baby.
• You should not breastfeed while using Nuvessa and for 2 days after treatment. Talk with your doctor about the best way to feed your baby during this time.

How to Store and Dispose of Nuvessa

The storage of Nuvessa (metronidazole vaginal gel 1.3%) is governed by mandatory temperature and packaging constraints defined in official labeling.

---

Storage Conditions

Nuvessa must be stored at controlled room temperature, specifically between 68 F and 77 F (20 C and 25 C). The regulatory guidance strictly prohibits refrigeration or freezing of the product.

Packaging rules require that the gel remain sealed within its original foil packet until the moment of administration. All medication must be kept out of the reach of children and pets.

---

Disposal Instructions

Unused or expired Nuvessa should be disposed of through a medicine take-back program. Regulatory documents advise against flushing the medication down the toilet or pouring it into a drain. If a take-back program is not available, local waste management should be consulted for proper disposal guidance.